Research Analysts’ Recent Ratings Updates for Innate Pharma (IPHA)

Several analysts have recently updated their ratings and price targets for Innate Pharma (NASDAQ: IPHA):

• 8/12/2026 – Innate Pharma had its price target raised by BTIG Research from $8.00 to $9.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Innate Pharma had its “buy” rating reaffirmed by UBS Group AG.
• 8/11/2026 – Innate Pharma was upgraded by Citigroup Inc. from “buy” to “outperform”.
• 8/11/2026 – Innate Pharma was upgraded by Leerink Partners from “market perform” to “outperform”. They now have a $4.00 price target on the stock.
• 8/10/2026 – Innate Pharma had its price target raised by HC Wainwright from $5.00 to $7.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Innate Pharma was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.